REMAP-HCM: Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - Sep 30, 2026 - P=N/A | N=800 | Not yet recruiting | Sponsor: Bristol-Myers Squibb
HEOR • New trial • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy
|